Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Abstract: The present invention relates inter alia to the use of a combination of a vaccine against Lawsonia intracellularis and an anti-Lawsonia antibiotic for the prevention or reduction of early, preferably fulminant Lawsonia intracellularis infections. The present invention relates particularly to the use of a live Lawsonia intracellularis vaccine in conjunction with an antibiotic that is effective against Lawsonia intracellularis, for the avoidance or reduction of early Lawsonia intracellularis infections in animals.

Abstract: The present invention pertains to the use of Streptococcus suis antigens corresponding to Streptococcus suis bacteria of a predetermined serotype in the manufacture of a vaccine for administration to a sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt, against a disorder arising from Streptococcus suis bacteria of a serotype other than the predetermined one. The invention also pertains to Streptococcus suis antigens for use in the manufacture of such a vaccine.

Abstract: The present invention provides a method of vaccinating a young animal against L. intracellularis infection comprising the step of administering to an animal an effective dose of L. intracellularis antigen. It also provides a method of vaccinating an animal, preferably a young animal, having anti-L. intracellularis antibodies or is exposed to anti-L. intracellularis antibodies. In particular, those anti-L.intracellularis antibodies are maternally derived antibodies.

Abstract: The invention relates to the use of ethylenediamine tetraacetic acid (EDTA) and its derivatives, i.e. its salts and complexes for prevention and treatment of bacterial intestinal diseases of pigs and for increasing the effects of antibiotics exerted in such diseases. The invention also relates to compositions for animal husbandry, i.e. to veterinary compositions and to feeds and drinks which can be consumed by pigs, comprising EDTA or its derivatives.

Abstract: The present invention relates inter alia to the use of a combination of a vaccine against Lawsonia intracellularis and an anti-Lawsonia antibiotic for the prevention or reduction of early, preferably fulminant Lawsonia intracellularis infections. The present invention relates particularly to the use of a live Lawsonia intracellularis vaccine in conjunction with an antibiotic that is effective against Lawsonia intracellularis, for the avoidance or reduction of early Lawsonia intracellularis infections in animals.

Abstract: The present invention provides improved vaccination methods for increased protection against ileitis. The methods provide for the vaccination of young animals, preferably piglets, between 10 and 26 days of age, vaccination of pregnant sows during the second or third stages of gestation, and a combination of these methods. Vaccination of the pregnant sows can occur using repeated and/or high doses of Lawsonia antigen prior to farrowing.

Abstract: Populations of Salmonella in animals may be substantially reduced by treatment with a vaccine composition which has been produced by exposing whole, intact cells of a Salmonella species to irradiation with an electron beam under conditions effective to kill the cells. The electron beam irradiated cells of Salmonella are effective for stimulating protective immune responses in the animals against the Salmonella. Induction of these immune responses significantly reduces or eliminates the colonization of the animal by the Salmonella, and consequently reduces or eliminates the shedding of Salmonella in the feces of the animals.

Abstract: The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.

Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

Abstract: The invention relates to stabilized antigen compositions of Erysipelothrix rhusiopathiae and vaccine formulations containing such antigen compositions. Antigens of the invention are effective in providing long-term protection against erysipelas in animals.

Abstract: The present invention provides compositions including at least two siderophore receptor polypeptides and at least two porins from a gram negative microbe, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of makino and methods of using such compositions.

Abstract: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. The present invention also contemplates methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting Lawsonia intracellularis or similar or otherwise related microorganism.

Abstract: A novel vaccine for immunizing animals against Staphylococcus aureus-induced mastitis is disclosed. The vaccine is comprised of whole killed cells of S. aureus in a dosage effective to immunize an animal against the organism, in combination with a pharmaceutically acceptable carrier.

Abstract: The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

Abstract: A new and improved formulation and method for making same, for a broad spectrum antimicrobial treatment for bacterial and viral infections in cattle, horses, pigs, sheep and other domestic and non-domestic animals. More particularly, the present invention relates to a treatment which enables rapid relief of symptoms in an affected animal with a mortality of less than 1 percent by providing trace organic minerals in microgram quantities which act as nutrients for the animal. The treatment provides further nutritional requirements in the form of vitamin A, folic acid and vitamin D3 supplements, cobalt amino acid chelates and dried kelp, a source of minerals, amino acids, simple and complex carbohydrates, iodine and fiber. In addition, a bacterial innoculum consisting of Acidophilus species is introduced which would inhibit growth of pathogenic or opportunistic species of bacteria by competition for nutrients as well as providing for required vitamins as a by-product of metabolism.

Abstract: A HERBAL OINTMENT for soothing aches and pains includes a mixture of clove oil, ginger oil, wintergreen oil, peppermint oil, ginger root powder, cayenne powder and petroleum jelly.

Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

Abstract: A live vaccine of recombinant mutants of a member of the family Pasteurellaceae lacking a rib gene necessary for production of riboflavin as well as a method of vaccination therewith is described. The vaccine is effective against members of the family Pasteurellaceae.

Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of strepococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

Abstract: The present invention relates to an isolated 17-kDa Brucclla antigen characterized by an amino acid sequence having at least 60% homology, preferably at least 70% homology, more preferably having at least 80% homology to the amino acid sequence as shown in SEQ ID No. 1 or 2, with said antigen being specifically recognized by sera from Brucella field infected individuals, more particulary an antigen characterized by the amino acid sequence as shown in SEQ ID No. 1 or 2. The invention also relates to recombinantly produced 17 kDa Brucella antigen, nucleic acids coding for the same and the use thereof in diagnostic and prophylactic methods and kits.

Abstract: A dietary supplement for nutritionally promoting healthy joint function in human subjects is disclosed. The supplement includes as a major ingredient a protein derived from the enzymatic hydrolysis of collagen in combination with lesser proportions of glucosamine sulfate, ginkgo biloba, borage oil powder, turmeric, boswellia serrata, ashwagandha, piper nigrum extract, and a herbal blend.

Abstract: This intention provides a method for enhancing a cell mediates immune response to Mycoplasma hypneumoniae in a newborn swine which involves administering a vaccine containing an effective amount of a protective antibody-inducing antigen to a pregnant sow, following by administering the vaccine to the newborn swine.

Abstract: Vaccines for diseases caused by normally encapsulated organisms are produced by genetically modifying those organisms by deleting the genes encoding for capsule synthesis or a portion thereof sufficient to produce non-capsulated mutants of the organisms. As an example, a live, attenuated strain of Actinobacillus pleuropneumoniae genetically modified with a large deletion in a chromosomal regions of the DNA which encodes for capsule synthesis is a safe and effective vaccine against swine pleuropneumonia.

Abstract: The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis.

Abstract: A new method for the preparation of a whole cell bacterial vaccine for improved protection against bacterial pathogens, particularly against those pathogens which have multiple antigenic serotypes is described. The method particularly involves disruption of the whole cells using a French press of the whole cells of virulent strains of the bacteria. The preferred vaccine prevented infection of swine with Actinobacillus pleuropneumoniae (APP), which causes porcine contagious pleuropneumonia. The vaccine has good safety and few side effects even at a higher dose than commonly used for bacterins and improved protection against the homologous serotype of the pathogen; and improved cross-protection against heterologous serotypes. The whole cell vaccine, is most useful for veterinary (lower mammal) vaccines.

Abstract: Novel bacterial preparations containing one or more isolated and purified strain of a microorganism which produces one or more RTX toxins, and which strain has at least one RTX toxin which is substantially cell-associated. Methods of preparing the bacterial preparations and their use as vaccines and to produce antibodies for passive immunization are described.

Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Bordetella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.

Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Abstract: A method of reversing or preventing immunosuppression or antigenic interference associated with combination vaccines in mammals, is disclosed. Cytokines, or cytokine inducer, are administered in conjunction with the combination vaccine. The cytokine or cytokine inducer can be administered concurrently with or subsequently to the vaccine, and can be recombinantly produced or isolated from cell culture.

Abstract: An improved method and vaccine is provided for the immunization of swine against infectious diseases caused by RTX toxin-secreting bacteria (e.g., porcine pleuropneumonia) which comprises administering to swine an effective amount of a live, immunizing, RTX toxin-secreting organism which induces in the swine a sufficiently high RTX toxin-neutralizing antibody titer to at least prevent clinical symptoms of the disease in the swine. For example, an intranasally administered, live, low virulence strain of A. suis (EM1) confers immunity upon swine against challenge with a virulent, disease-causing strain of A. pleuropneunmoniae.

Abstract: A method for large scale cultivation and attenuation of L. intracellularis bacteria by inoculating cells with L. intracellularis bacteria to infect the cells, incubating the infected cells in a reduced oxygen concentration and maintaining the infected cells in suspension. Anti-L. intracellularis vaccines are prepared from cultures grown in suspension. Diagnostic agents are also disclosed.

Abstract: Compounds and pharmaceutical compositions thereof comprise the formula:(R)j-(core moiety),including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten, R'.sub.1 and R'.sub.

Abstract: The present invention relates to a polypeptide of the bacterium Streptococcus suis with a molecular weight of about 54 kD, capable of inducing neutralising antibodies against Streptococcus suis. The invention also relates to a vaccine against Streptococcus suis infection, and a method for the preparation of such a vaccine.

Abstract: This invention provides a bacterin comprising a virulent Mycoplasma hyopneumoniae isolate, inactivated with binary ethyleneimine, in an amount effective to immunize a swine against infection by Mycoplasma hyopneumoniae and a suitable physiologically acceptable carrier. The invention also provides a method of producing this bacterin. The invention further provides a method of inactivating a virulent strain of Mycoplasma hyopneumoniae by contacting the Mycoplasma hyopneumoniae with binary ethyleneimine. Finally, the invention also provides a method of immunizing swine against infection by Mycoplasma hyopneumoniae comprising administering to the swine a dose of the bacterin so as to immunize the swine.

Abstract: Administering a feed composition, containing at least one member selected from the group consisting of sterilized bacterial cells; disrupted cell fragments obtained by mechanical disruption or enzymatic decomposition of the cells and cell wall component-containing fractions obtained by fractionation of the disrupted cell fragments, to pregnant sows and mother sows results in a reduction in stillborn piglets, a decrease in mortality during the breast-feeding period, a reduction in the occurrence of diarrhea during the breast-feeding period, and an increase in body weight of piglets.

Abstract: The invention is directed to a method for immunizing an animal for the production of high levels of IgA antibodies against a lung pathogen. The method comprises administering an antigen by transthoracic injection directly into the lung of the animal, the elicited antibodies having specific activity against the administered antigen and lung pathogen of interest. The invention provides a method of stimulating the production of IgA antibodies at mucosal surfaces of the lungs to increase IgA antibody titers in lung fluids and reduce the severity of the lung disease of interest.

Abstract: Novel vaccines for use against Actinobacillus pleuropneumoniae are disclosed. The vaccines contain at least one Actinobacillus pleuropneumoniae outer membrane lipoprotein A, or an immunogenic fragment thereof. Also disclosed are DNA sequences encoding these proteins, vectors including these sequences and host cells transformed with these vectors. The vaccines can be used to treat or prevent porcine respiratory infections.

Abstract: Noncapsulated mutants of normally encapsulated bacteria in which the capsule is required for virulence are useful as vaccines for disease states caused by the normally encapsulated bacteria. In particular, a non-capsulated mutant of Actinobacillus (Haemophilus) pleuropneumoniae is useful in protecting against swine pleuropneumonia.

Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Borderella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.

Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Bordetella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.